# Postmenopausal osteoporosis Market

> Postmenopausal Osteoporosis Market Research Report Information By Drug Class (Bisphosphonates, Selective Estrogen Receptor Modulators (SERMs), Anabolic Class, RANK Ligand Inhibitors, Calcium Metabolism Modifiers, and Others), By Route of Administration (Oral, Intravenous Route, and Subcutaneous), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 5.9%
- **2024:** $ 10.2 Billion
- **2025:** $ 10.8 Billion
- **2035:** $ 19.17 Billion
- **Key Players:** Amgen Inc (US), Bristol-Myers Squibb Company (US), Eli Lilly and Company (US), Novartis AG(CH), Pfizer Inc (US), Sanofi S.A. (FR), Teva Pharmaceutical Industries Ltd (IL), Horizon Therapeutics plc (IE), Mylan N.V. (US)

**Report ID:** MRFR/HC/20324-HCR · **Pages:** 128 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** May 15, 2026

**URL:** https://www.marketresearchfuture.com/reports/postmenopausal-osteoporosis-market-21923

---

## Market Summary

## **Global Postmenopausal Osteoporosis Market Overview**

The Postmenopausal Osteoporosis Market Size was valued at USD 9.7 billion in 2023. The Postmenopausal Osteoporosis Market industry is projected to grow from USD 10.2 billion in 2024 to USD 15.3 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.90% during the forecast period (2024 - 2032). Rising osteoporosis incidence among elderly females and increasing R&D and new drug approvals are the primary market drivers propelling the market's expansion.

Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review

## **Postmenopausal Osteoporosis Market Trends**

### **Increasing demand for bisphosphonates is driving the market growth**

The capacity of the bisphosphonates family of drugs to stop bone density loss and hence reduce fracture risk by 50% is predicted to account for the biggest proportion of the market. Moreover, most patients are able to take bisphosphonates over the long term. For instance, as per an article published in April 2021, named 'Bisphosphonate Prescriptions for Osteoporosis: Concerns In regards to Dangers and Side Effects,' by restraining osteoclast action, bisphosphonates diminish bone resorption, and various examinations have shown the way that this group of medications can increment bone thickness and lower break risk in those with low bone thickness.

Because most patients with osteoporosis receive frequent prescriptions for them, it is anticipated that they will hold a sizable portion of the market under investigation.

Several bisphosphonates are often used to avoid and treat postmenopausal osteoporosis, including alendronate, risedronate, ibandronate, and zoledronic acid. A new regimen, including the intravenous approach, is being studied; positive trial results might further drive the bisphosphonate business throughout the anticipated time frame. The average five-year prescription for bisphosphonates lasts, and the drug's bone-protective effects last long after the course of therapy is stopped. Therefore, it is anticipated that the bisphosphate category would have a sizable market share in the postmenopausal osteoporosis market due to the considerations above.

Additionally, targeting certain processes involved in bone metabolism, such as sclerostin inhibition or the RANK ligand pathway, is the goal of biological treatments. Biologics can improve bone production and reduce bone resorption by carefully adjusting these pathways, providing a more focused and efficient method of treating osteoporosis, which is driving the market CAGR. In patients who are at high risk of fractures or who do not respond well to standard pharmacological medications, biologic therapies have proven to be more effective than traditional ones.

This increased effectiveness may result in better results, such as decreased risk of fracture and increased density of bone mineral.

Furthermore, as per information distributed by the Worldwide Menopause Society (IMS), in 2021, more than 200 million ladies are assessed to experience the ill effects of osteoporosis, and 1 of every three ladies matured more than 50 is supposed to encounter osteoporosis fracture. Due to the previously mentioned factors, the concentrated market is supposed to develop over the estimated period. Thus driving the Postmenopausal Osteoporosis market revenue.

## **Postmenopausal Osteoporosis Market Segment Insights**

### **Postmenopausal Osteoporosis Drug Class Insights**

Based on Drug Class, the Postmenopausal Osteoporosis market segmentation includes bisphosphonates, selective estrogen receptor modulators (SERMs), anabolic class, RANK ligand inhibitors, calcium metabolism modifiers, and others. In 2023, the bisphosphonates segment dominated the market. Postmenopausal osteoporosis is treated with meds of the bisphosphonate family. By preventing bone resorption, it raises bone density in this way. Trends presently suggest a shift toward more contemporary biopharmaceuticals and accurate designated prescriptions, despite the fact that bisphosphonates have generally been a significant piece of osteoporosis treatment.

However, market patterns suggest that patients are progressively more intrigued by inventive meds that might make fewer side impacts and better understand results. However, bisphosphonates are still frequently endorsed because of their shown adequacy. This improvement is an impression of the continuous mission for further developed and concentrated postmenopausal osteoporosis treatment.

The selective estrogen receptor modulators (SERMs) category is anticipated to be the fastest growing. Clinical experimentation has shown the viability of SERMs, for example, raloxifene, in decreasing the risk of vertebral fractures in postmenopausal ladies with osteoporosis. This decrease in break risk is a key component driving interest in SERMs as a treatment choice. Compared to standard hormone replacement therapy (HRT), SERMs provide a substitute for controlling postmenopausal side effects and reducing fractures caused by osteoporosis. They give a portion of the advantages of estrogen treatment, like bone protection, without the related dangers, like an expanded hazard of breast disease.

### **Postmenopausal Osteoporosis Route of Administration Insights**

Based on the Route of Administration, the Postmenopausal Osteoporosis market segmentation includes oral, intravenous route, and subcutaneous. In 2023, the oral category generated the most income. Because it is more convenient and straightforward to administer, patients frequently choose the oral route. Because oral drugs don't require injections or infusions, patients are better able to comply with their treatment plans and stay compliant. Because oral administration is painless and often well tolerated by patients, it reduces the risk of infusion-related adverse events or infusion-site reactions that are typically associated with other administration methods.

Throughout the forecast period, the market for postmenopausal osteoporosis intravenous routes is expected to develop at the quickest rate. Certain drugs that treat osteoporosis, such as bisphosphonates (like zoledronic acid), are infused intravenously. One yearly or biennial dosage is a benefit of infusion therapy; this lowers the frequency of drug delivery and may increase patient convenience and adherence.

### **Postmenopausal Osteoporosis Distribution Channel Insights**

Based on the Distribution Channel, the Postmenopausal Osteoporosis market segmentation includes hospital pharmacies, retail pharmacies, and online pharmacies. The retail pharmacies category leads the market. Patients can seek guidance and support services from retail drug stores, like assistance with adherence, portion guidelines, and medication directing. With regards to illuminating patients about their osteoporosis medicates, their side effects, and the benefit of adhering to treatment plans, drug specialists are essential. Patients generally visit retail drug stores to finish their solutions for osteoporosis drugs that clinical experts have suggested.

The Postmenopausal Osteoporosis market’s online pharmacies segment is anticipated to grow fastest during the projection period. For those with mobility impairments, who reside in rural locations, or who prefer to obtain drugs conveniently from the comfort of their homes, online pharmacies offer easy access to osteoporosis treatments.

**Figure 1:  Postmenopausal Osteoporosis Market, by Distribution Channel, 2023 & 2032 (USD Billion)**

****

Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review

### **Postmenopausal Osteoporosis Regional Insights**

By region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North American Postmenopausal Osteoporosis market will dominate this market because of its developed medical care framework, presence of significant industry players, high diagnosis and therapy rate, more patient consistency, and huge patient base. The US contributes the most extreme offer in North America. About 18.8% of women who were 50 years of age or older had osteoporosis, according to data released by the Centers for Disease Control and Prevention (CDC) in 2021.

Sedentary lifestyles and bad eating and drinking habits are expected to contribute to the pervasiveness even further. Approximately 71 million Americans are expected to have reduced bone density and osteoporosis by 2030, according to the Public Osteoporosis Establishment.

Further, the major countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

**Figure 2:  POSTMENOPAUSAL OSTEOPOROSIS MARKET SHARE BY REGION 2023 (USD Billion)**

****

Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review

Europe's Postmenopausal Osteoporosis market accounts for the second-largest market share. Europe's population is among the oldest in the world, and a significant number of postmenopausal women live in regions where osteoporosis is more common. The demographic shift towards an aging population creates an important market for osteoporosis prevention, diagnosis, and treatment. Further, the German Postmenopausal Osteoporosis market held the largest market share, and the UK Postmenopausal Osteoporosis market was the fastest-growing market in the European region.

The Asia-Pacific Postmenopausal Osteoporosis Market is expected to grow at the fastest CAGR from 2024 to 2032. Numerous nations in the Asia Pacific are putting resources into extending their healthcare framework, further developing admission to healthcare administrations, and reinforcing primary care systems. This development of healthcare facilities and services upgrades opportunities for osteoporosis screening, analysis, and therapy. Moreover, China’s Postmenopausal Osteoporosis market held the largest market share, and the Indian Postmenopausal Osteoporosis market was the fastest-growing market in the Asia-Pacific region.

## **Postmenopausal Osteoporosis Key Market Players & Competitive Insights**

The industry's leading players will keep investing heavily in R&D to expand their product lines, which will propel the growth of the postmenopausal osteoporosis market. Contractual contracts, mergers and acquisitions, increased investments, collaboration with other companies, and the production of new products are examples of significant market developments. To increase their worldwide reach, market players also take part in a variety of strategic initiatives. In order to survive and expand in a more competitive and dynamic market, the Postmenopausal Osteoporosis industry must offer reasonably priced products and services.

One of the main strategies manufacturers use in the worldwide Postmenopausal Osteoporosis market is local manufacturing, which expands the market sector and helps customers by lowering operating costs. Some of the biggest medical benefits in recent years have come from the Postmenopausal Osteoporosis sector. Major players in the Postmenopausal Osteoporosis market, including Pfizer Inc., Amgen, F.

Hoffmann-La Roche Ltd, Novartis AG, Chugai Pharma China Co., Ltd., Teva Pharmaceutical Industries Ltd., Fresenius Kabi AG, Hikma Pharmaceuticals PLC, GlaxoSmithKline plc, Sun Pharmaceutical Industries Ltd, Paras Biopharmaceuticals Finland Oy, Ligand Pharmaceuticals Incorporated, and Eli Lilly and Company, and others, are attempting to increase market demand by investing in research and development operations.

Pfizer Inc (Pfizer) discovers, creates, makes, and markets biopharmaceuticals. The organization offers items to treat different circumstances, such as cardiovascular, metabolic, and pain, ladies' well-being, malignant growth, inflammation, resistant problems, and rare illnesses. It additionally gives clean injectable drugs, biosimilars, active pharmaceutical ingredients (APIs), and agreement-producing services. Pfizer sells its items through wholesalers, retailers, medical clinics, individual supplier workplaces, facilities, government organizations, and drug stores. Pfizer Inc. brought back to the U.S. market DUAVEE (conjugated estrogens/bazedoxifene), a menopausal hormone treatment with estrogen, in June 2023 with improved packaging.

This return follows a voluntary recall due to a packaging problem that had nothing to do with any worries about the efficacy or safety of the product. It is anticipated that this relaunch plan will address the packaging concerns and increase sales income.

Amgen Inc., a biotechnology business, finds, makes, produces, and distributes state-of-the-art human meds to treat patients with hazardous sicknesses. It makes state-of-the-art prescriptions to address afflictions connected with the heart, hematological and oncology, irritation, bone well-being, neurological sicknesses, and nephrology. To make merchandise that uses state-of-the-art human hereditary qualities, the association inspects the difficulties presented by sickness and appreciates the standards of human science. Amgen mainly supplies pharmaceutical wholesale wholesalers in the United States with its goods. Additionally, it markets some items directly to customers through collaborations with other businesses and direct-to-consumer channels.

Amgen's latest findings from real-world research in 2023 show that Prolia was very successful in lowering the risk of fracture in individuals with postmenopausal osteoporosis.

### **Key companies in the Postmenopausal Osteoporosis market include**

- [Pfizer Inc](https://www.pfizer.com/news/announcements/pfizer-announces-duaveer-conjugated-estrogensbazedoxifene-estrogen-based).
- Amgen
- [Hoffmann-La Roche Ltd](https://diagnostics.roche.com/global/en/article-listing/roche-bone-markers-for-an-improved-management-of-osteoporosis-pa.html)
- Novartis AG
- Chugai Pharma China Co., Ltd.
- Teva Pharmaceutical Industries Ltd.
- Fresenius Kabi AG
- Hikma Pharmaceuticals PLC
- GlaxoSmithKline plc
- Sun Pharmaceutical Industries Ltd
- Paras Biopharmaceuticals Finland Oy
- Ligand Pharmaceuticals Incorporated
- Eli Lilly and Company

## **Postmenopausal Osteoporosis Industry Developments**

**July 2022:** Edirol (eldecalcitol) was introduced in China by Chugai Pharma China Co., Ltd., a division of Chugai Pharmaceutical Co., Ltd., following clearance by the China National Medical Products Administration (NMPA) for the management of postmenopausal osteoporosis. Chugai developed edirol, an effective vitamin D3 derivative.

**January 2021:** Released by the Asia Pacific Consortium on Osteoporosis (APCO), the guidelines provide clinical practice for osteoporosis screening, diagnosis, and care throughout the Asia-Pacific region. The guidelines prioritize the needs of several high-risk populations. In addition to strengthening the Asia-Pacific sector, the project is expected to increase awareness in the region even further.

**In May 2024**, Fresenius Kabi stated that the FDA has approved for evaluation the company's Biologics License Application (BLA) for FKS518, its biosimilar candidate to Prolia (denosumab) and Xgeva (denosumab) for the treatment of postmenopausal osteoporosis

**In June 2023**, Pfizer Inc. returned DUAVEE (conjugated estrogens/bazedoxifene), a menopausal hormone treatment including estrogen, to the US market with improved packaging. This return follows a voluntary recall caused by a packaging problem that was unconnected to any concerns about the product's efficacy or safety. This relaunch technique is supposed to ease packaging difficulties while also generating income through sales.

**In February 2023**, Sandoz obtained a Biologics License Application (BLA) from the US Food and Drug Administration (FDA) for a potential denosumab biosimilar (Prolia and Xgeva; Amgen). The medicine is meant to treat a wide range of illnesses, including osteoporosis in postmenopausal women and men at high risk of fracture and a variety of other medical disorders

## **Postmenopausal Osteoporosis Market Segmentation**

### **Postmenopausal Osteoporosis Drug Class Outlook**

- Bisphosphonates
- Selective Estrogen Receptor Modulators (SERMs)
- Anabolic Class
- RANK Ligand Inhibitors
- Calcium Metabolism Modifiers
- Others

### **Postmenopausal Osteoporosis Route of Administration Outlook**

- [Oral](../../../reports/oral-cancer-treatment-market-1820)
- Intravenous Route
- Subcutaneous

### **Postmenopausal Osteoporosis Distribution Channel Outlook**

- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies

### **Postmenopausal Osteoporosis Regional Outlook**

## Market Drivers

### Growing Geriatric Population

The expanding geriatric population is a significant factor influencing the Postmenopausal Osteoporosis Market. As life expectancy increases, the number of older adults, particularly women, is on the rise. This demographic shift is expected to result in a higher prevalence of osteoporosis, as age is a critical risk factor for the disease. Projections indicate that by 2030, the number of individuals aged 65 and older will surpass 1 billion, further intensifying the demand for osteoporosis management solutions. Consequently, pharmaceutical companies and healthcare providers are likely to focus their efforts on developing targeted therapies and interventions for this population. The Postmenopausal Osteoporosis Market is poised for growth as stakeholders respond to the needs of an aging society.

### Rising Incidence of Osteoporosis

The increasing incidence of osteoporosis among postmenopausal women is a primary driver of the Postmenopausal Osteoporosis Market. Studies indicate that approximately 50% of women over the age of 50 will experience an osteoporosis-related fracture in their lifetime. This alarming statistic underscores the urgent need for effective treatment options and preventive measures. As the population ages, the prevalence of osteoporosis is expected to rise, leading to a greater demand for medications and therapies. The Postmenopausal Osteoporosis Market is likely to see significant growth as healthcare providers and patients seek solutions to manage and mitigate the risks associated with this condition. Furthermore, the economic burden of osteoporosis-related fractures, estimated to reach billions annually, further propels investment in research and development within this market.

### Regulatory Support and Guidelines

Regulatory support and the establishment of clinical guidelines are pivotal drivers of the Postmenopausal Osteoporosis Market. Regulatory agencies are increasingly recognizing the importance of addressing osteoporosis, leading to the development of comprehensive guidelines for diagnosis and treatment. These guidelines not only facilitate better patient management but also encourage healthcare providers to adopt evidence-based practices. Furthermore, the approval of new therapies by regulatory bodies enhances market confidence and stimulates investment in osteoporosis research. As healthcare systems align with these guidelines, the demand for effective treatment options is likely to increase, thereby propelling the growth of the Postmenopausal Osteoporosis Market. The collaborative efforts between regulatory agencies and healthcare providers are expected to yield positive outcomes for patients and the market alike.

### Increased Focus on Preventive Healthcare

The growing emphasis on preventive healthcare is a notable driver of the Postmenopausal Osteoporosis Market. As awareness of osteoporosis and its consequences rises, more healthcare professionals and patients are prioritizing preventive measures. This shift is reflected in the increasing adoption of lifestyle modifications, such as dietary changes and exercise regimens, aimed at reducing the risk of osteoporosis. Furthermore, healthcare systems are increasingly integrating screening programs to identify at-risk individuals early. This proactive approach not only enhances patient outcomes but also drives demand for related products and services within the Postmenopausal Osteoporosis Market. The potential for early intervention is likely to lead to a decrease in fracture rates, thereby reducing the overall healthcare costs associated with osteoporosis.

### Advancements in Pharmaceutical Treatments

Innovations in pharmaceutical treatments for postmenopausal osteoporosis are reshaping the Postmenopausal Osteoporosis Market. Recent advancements have led to the development of new classes of medications, including monoclonal antibodies and bisphosphonates, which have shown promising results in increasing bone density and reducing fracture risk. The introduction of these novel therapies is expected to enhance patient compliance and outcomes, thereby expanding the market. Additionally, the global market for osteoporosis drugs is projected to grow significantly, with estimates suggesting a compound annual growth rate of over 5% in the coming years. This growth is indicative of the increasing investment in research and development, as well as the ongoing need for effective treatment options for postmenopausal women.

## Future Outlook

The Postmenopausal Osteoporosis Market is projected to grow at a 5.9% CAGR from 2025 to 2035, driven by increasing awareness, aging populations, and advancements in treatment options.

**New opportunities:**

- Development of digital health platforms for remote patient monitoring
- Expansion of [personalized medicine](https://www.marketresearchfuture.com/reports/personalized-medicine-market-2937) approaches in osteoporosis treatment
- Investment in educational programs for healthcare providers on osteoporosis management

By 2035, the market is expected to be robust, driven by innovation and increased patient engagement.

## Segment Insights

### By Drug Class: Bisphosphonates (Largest) vs. RANK Ligand Inhibitors (Fastest-Growing)

In the Postmenopausal Osteoporosis Market, Bisphosphonates have established themselves as the largest segment, holding a significant share due to their effectiveness in reducing fracture risk. This class has seen widespread adoption among healthcare providers, leading to high market penetration. Selective Estrogen Receptor Modulators and Anabolic Class also contribute to the overall market, but their share remains comparatively smaller. Rising awareness about osteoporosis prevention and treatment further boosts the adoption of these therapeutic options. The market is currently witnessing a surge in interest towards RANK Ligand Inhibitors, identified as the fastest-growing segment. This growth can be attributed to their novel mechanism of action, which provides an effective alternative for patients who are intolerant to traditional therapies. Additionally, favorable clinical trial results and physician endorsement are encouraging prescribers to explore these innovative options, further transforming the treatment landscape for postmenopausal osteoporosis.

Bisphosphonates (Dominant) vs. RANK Ligand Inhibitors (Emerging)

Bisphosphonates have become the dominant choice in the Postmenopausal Osteoporosis Market, primarily due to their robust clinical efficacy and solidified guidelines endorsing their use for fracture prevention. These agents work by inhibiting osteoclast-mediated bone resorption, which helps maintain bone density. Additionally, the extensive clinical history and familiarity among healthcare providers reinforce their market position. In contrast, RANK Ligand Inhibitors represent an emerging and innovative class that specifically targets the RANK/RANKL/OPG pathway, substantially reducing the frequency of vertebral and non-vertebral fractures. Their novel approach offers a unique solution for patients with high fracture risk, thus attracting significant therapeutic interest and investment due to their potential for high efficacy and improved patient adherence.

### By Route of Administration: Oral (Largest) vs. Intravenous Route (Fastest-Growing)

In the Postmenopausal Osteoporosis Market, the route of administration is critical in determining patient adherence and treatment efficacy. Oral administration currently holds the largest share, favored for its convenience and ease of use, appealing to most patients. Intravenous route and subcutaneous administration also represent significant portions of the market but show varied patient acceptance and implementation in clinical settings.

Route of Administration: Oral (Dominant) vs. Intravenous Route (Emerging)

The oral administration route remains dominant in the Postmenopausal Osteoporosis Market, primarily due to its user-friendly nature. Patients prefer oral medications as they offer a non-invasive, straightforward method of treatment. Meanwhile, intravenous administration, identified as the fastest-growing segment, is increasingly utilized in hospitals and clinical settings for its rapid action and higher bioavailability, appealing to patients requiring immediate results. The subcutaneous route, while present in the market, is more niche, attracting specific patient populations needing tailored therapies. As awareness and education progress, the preference towards oral and intravenous solutions seems poised for continued growth.

### By Distribution Channel: Hospital Pharmacies (Largest) vs. Online Pharmacies (Fastest-Growing)

In the Postmenopausal Osteoporosis Market, the distribution of pharmaceutical products through various channels reveals significant trends. Hospital pharmacies hold the largest share, serving as crucial access points for patients receiving treatments during hospital stays. Meanwhile, retail pharmacies also contribute substantially, but online pharmacies are emerging rapidly as a key player, reflecting shifting consumer preferences toward digital solutions.

Hospital Pharmacies (Dominant) vs. Online Pharmacies (Emerging)

Hospital pharmacies are well-established and primarily cater to patients undergoing treatment in clinical settings. They provide essential medications, including those for postmenopausal osteoporosis, ensuring immediate access to therapies tailored for individual patient needs. With healthcare providers directly influencing prescriptions, these pharmacies maintain a dominant market position. On the other hand, online pharmacies are becoming increasingly popular, driven by the growing trend of telemedicine and the convenience of home delivery. This segment attracts a tech-savvy demographic looking for easier access to osteoporosis treatments, signaling an emerging shift in pharmaceutical distribution.

## Regional Market Share Analysis

By region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North American Postmenopausal Osteoporosis market will dominate this market because of its developed medical care framework, presence of significant industry players, high diagnosis and therapy rate, more patient consistency, and huge patient base. The US contributes the most extreme offer in North America. About 18.8% of women who were 50 years of age or older had osteoporosis, according to data released by the Centers for Disease Control and Prevention (CDC) in 2021.

Sedentary lifestyles and bad eating and drinking habits are expected to contribute to the pervasiveness even further. Approximately 71 million Americans are expected to have reduced bone density and osteoporosis by 2030, according to the Public Osteoporosis Establishment.

Further, the major countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

**Figure 2:  POSTMENOPAUSAL OSTEOPOROSIS MARKET SHARE BY REGION 2023 (USD Billion)**

Europe's Postmenopausal Osteoporosis market accounts for the second-largest market share. Europe's population is among the oldest in the world, and a significant number of postmenopausal women live in regions where osteoporosis is more common. The demographic shift towards an aging population creates an important market for osteoporosis prevention, diagnosis, and treatment. Further, the German Postmenopausal Osteoporosis market held the largest market share, and the UK Postmenopausal Osteoporosis market was the fastest-growing market in the European region.

The Asia-Pacific Postmenopausal Osteoporosis Market is expected to grow at the fastest CAGR from 2024 to 2032. Numerous nations in the Asia Pacific are putting resources into extending their healthcare framework, further developing admission to healthcare administrations, and reinforcing primary care systems. This development of healthcare facilities and services upgrades opportunities for osteoporosis screening, analysis, and therapy. Moreover, China’s Postmenopausal Osteoporosis market held the largest market share, and the Indian Postmenopausal Osteoporosis market was the fastest-growing market in the Asia-Pacific region.

## Competitive Benchmarking

The industry's leading players will keep investing heavily in R&D to expand their product lines, which will propel the growth of the postmenopausal osteoporosis market. Contractual contracts, mergers and acquisitions, increased investments, collaboration with other companies, and the production of new products are examples of significant market developments. To increase their worldwide reach, market players also take part in a variety of strategic initiatives. In order to survive and expand in a more competitive and dynamic market, the Postmenopausal Osteoporosis industry must offer reasonably priced products and services.
One of the main strategies manufacturers use in the worldwide Postmenopausal Osteoporosis market is local manufacturing, which expands the market sector and helps customers by lowering operating costs. Some of the biggest medical benefits in recent years have come from the Postmenopausal Osteoporosis sector. Major players in the Postmenopausal Osteoporosis market, including Pfizer Inc., Amgen, F.
Hoffmann-La Roche Ltd, Novartis AG, Chugai Pharma China Co., Ltd., Teva Pharmaceutical Industries Ltd., Fresenius Kabi AG, Hikma Pharmaceuticals PLC, GlaxoSmithKline plc, Sun Pharmaceutical Industries Ltd, Paras Biopharmaceuticals Finland Oy, Ligand Pharmaceuticals Incorporated, and Eli Lilly and Company, and others, are attempting to increase market demand by investing in research and development operations.
Pfizer Inc (Pfizer) discovers, creates, makes, and markets biopharmaceuticals. The organization offers items to treat different circumstances, such as cardiovascular, metabolic, and pain, ladies' well-being, malignant growth, inflammation, resistant problems, and rare illnesses. It additionally gives clean injectable drugs, biosimilars, active pharmaceutical ingredients (APIs), and agreement-producing services. Pfizer sells its items through wholesalers, retailers, medical clinics, individual supplier workplaces, facilities, government organizations, and drug stores. Pfizer Inc. brought back to the U.S. market DUAVEE (conjugated estrogens/bazedoxifene), a menopausal hormone treatment with estrogen, in June 2023 with improved packaging.
This return follows a voluntary recall due to a packaging problem that had nothing to do with any worries about the efficacy or safety of the product. It is anticipated that this relaunch plan will address the packaging concerns and increase sales income.
Amgen Inc., a biotechnology business, finds, makes, produces, and distributes state-of-the-art human meds to treat patients with hazardous sicknesses. It makes state-of-the-art prescriptions to address afflictions connected with the heart, hematological and oncology, irritation, bone well-being, neurological sicknesses, and nephrology. To make merchandise that uses state-of-the-art human hereditary qualities, the association inspects the difficulties presented by sickness and appreciates the standards of human science. Amgen mainly supplies pharmaceutical wholesale wholesalers in the United States with its goods. Additionally, it markets some items directly to customers through collaborations with other businesses and direct-to-consumer channels.
Amgen's latest findings from real-world research in 2023 show that Prolia was very successful in lowering the risk of fracture in individuals with postmenopausal osteoporosis.

## Recent News & Developments

**July 2022:** Edirol (eldecalcitol) was introduced in China by Chugai Pharma China Co., Ltd., a division of Chugai Pharmaceutical Co., Ltd., following clearance by the China National Medical Products Administration (NMPA) for the management of postmenopausal osteoporosis. Chugai developed edirol, an effective vitamin D3 derivative.

**January 2021:** Released by the Asia Pacific Consortium on Osteoporosis (APCO), the guidelines provide clinical practice for osteoporosis screening, diagnosis, and care throughout the Asia-Pacific region. The guidelines prioritize the needs of several high-risk populations. In addition to strengthening the Asia-Pacific sector, the project is expected to increase awareness in the region even further.

**In May 2024**, Fresenius Kabi stated that the FDA has approved for evaluation the company's Biologics License Application (BLA) for FKS518, its biosimilar candidate to Prolia (denosumab) and Xgeva (denosumab) for the treatment of postmenopausal osteoporosis

**In June 2023**, Pfizer Inc. returned DUAVEE (conjugated estrogens/bazedoxifene), a menopausal hormone treatment including estrogen, to the US market with improved packaging. This return follows a voluntary recall caused by a packaging problem that was unconnected to any concerns about the product's efficacy or safety. This relaunch technique is supposed to ease packaging difficulties while also generating income through sales.

**In February 2023**, Sandoz obtained a Biologics License Application (BLA) from the US Food and Drug Administration (FDA) for a potential denosumab biosimilar (Prolia and Xgeva; Amgen). The medicine is meant to treat a wide range of illnesses, including osteoporosis in postmenopausal women and men at high risk of fracture and a variety of other medical disorders

## Report Scope

| MARKET SIZE 2024 | 10.2(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 10.8(USD Billion) |
| MARKET SIZE 2035 | 19.17(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.9% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Amgen Inc (US), Bristol-Myers Squibb Company (US), Eli Lilly and Company (US), Novartis AG (CH), Pfizer Inc (US), Sanofi S.A. (FR), Teva Pharmaceutical Industries Ltd (IL), Horizon Therapeutics plc (IE), Mylan N.V. (US) |
| Segments Covered | Drug Class, Route of Administration, Distribution Channel, Region |
| Key Market Opportunities | Advancements in biologics and personalized medicine enhance treatment options in the Postmenopausal Osteoporosis Market. |
| Key Market Dynamics | Rising demand for innovative therapies drives competition and regulatory scrutiny in the Postmenopausal Osteoporosis Market. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the current valuation of the Postmenopausal Osteoporosis Market?**
A: The market valuation was 10.2 USD Billion in 2024.

**Q: What is the projected market size for the Postmenopausal Osteoporosis Market by 2035?**
A: The market is expected to reach 19.17 USD Billion by 2035.

**Q: What is the expected CAGR for the Postmenopausal Osteoporosis Market during the forecast period?**
A: The expected CAGR for the market from 2025 to 2035 is 5.9%.

**Q: Which drug class segment holds the highest market value in the Postmenopausal Osteoporosis Market?**
A: The Bisphosphonates segment had a valuation of 3.5 to 6.5 USD Billion.

**Q: How does the Oral route of administration compare to others in terms of market value?**
A: The Oral route had a market value ranging from 4.5 to 8.5 USD Billion.

**Q: What are the projected values for the RANK Ligand Inhibitors segment by 2035?**
A: The RANK Ligand Inhibitors segment is projected to reach 1.2 to 2.0 USD Billion.

**Q: Which distribution channel is expected to show significant growth in the Postmenopausal Osteoporosis Market?**
A: Retail Pharmacies had a market value of 4.08 to 7.67 USD Billion.

**Q: Who are the key players in the Postmenopausal Osteoporosis Market?**
A: Key players include Amgen Inc, Bristol-Myers Squibb Company, and Eli Lilly and Company.

**Q: What is the market value range for the Anabolic Class segment?**
A: The Anabolic Class segment had a valuation of 1.0 to 3.0 USD Billion.

**Q: What is the expected market trend for Online Pharmacies in the Postmenopausal Osteoporosis Market?**
A: Online Pharmacies are projected to reach a market value of 3.06 to 5.77 USD Billion.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/postmenopausal-osteoporosis-market-21923*